168 related articles for article (PubMed ID: 28361167)
41. Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France.
Houédé N; Beuzeboc P; Gourgou S; Tosi D; Moise L; Gravis G; Delva R; Fléchon A; Latorzeff I; Ferrero JM; Oudard S; Tartas S; Laguerre B; Topart D; Roubaud G; Agherbi H; Rebillard X; Azria D
BMC Cancer; 2015 Apr; 15():222. PubMed ID: 25884302
[TBL] [Abstract][Full Text] [Related]
42. CYP17A1 polymorphisms and clinical outcome of castration-resistant prostate cancer patients treated with abiraterone.
Salvi S; Casadio V; Burgio SL; Conteduca V; Rossi L; Menna C; Carretta E; Costantini M; Zoli W; De Giorgi U
Int J Biol Markers; 2016 Jul; 31(3):e264-9. PubMed ID: 26954071
[TBL] [Abstract][Full Text] [Related]
43. Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment.
Aggarwal R; Harris A; Formaker C; Small EJ; Molina A; Griffin TW; Ryan CJ
Clin Genitourin Cancer; 2014 Oct; 12(5):e167-72. PubMed ID: 24787968
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
[TBL] [Abstract][Full Text] [Related]
45. Bilateral Choroidal Metastases from Prostate Cancer revealed in a patient under Abiraterone - Fourteen years after diagnosis.
Kourie HR; Antoun J; Bteich F; Jalkh A; Ghosn M
Gulf J Oncolog; 2016 May; 1(21):67-9. PubMed ID: 27250892
[TBL] [Abstract][Full Text] [Related]
46. Quantitation of the anticancer drug abiraterone and its metabolite Δ(4)-abiraterone in human plasma using high-resolution mass spectrometry.
Bhatnagar A; McKay MJ; Crumbaker M; Ahire K; Karuso P; Gurney H; Molloy MP
J Pharm Biomed Anal; 2018 May; 154():66-74. PubMed ID: 29533860
[TBL] [Abstract][Full Text] [Related]
47. Prevalence of drug-drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management.
Bellesoeur A; Gataa I; Jouinot A; Mershati SE; Piketty AC; Tlemsani C; Balakirouchenane D; Monribot A; Vidal M; Batista R; de Percin S; Villeminey C; Alexandre J; Goldwasser F; Blanchet B; Boudou-Rouquette P; Thomas-Schoemann A
Cancer Chemother Pharmacol; 2021 Oct; 88(4):741-751. PubMed ID: 34304283
[TBL] [Abstract][Full Text] [Related]
48. Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: A case report and review of the literature.
Dineen M; Hansen E; Guancial E; Sievert L; Sahasrabudhe D
J Oncol Pharm Pract; 2018 Jun; 24(4):314-318. PubMed ID: 28355968
[TBL] [Abstract][Full Text] [Related]
49. A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration-resistant metastatic prostate cancer.
Benoist GE; van der Doelen MJ; Ter Heine R; van Erp NP; Mehra N
Br J Clin Pharmacol; 2018 May; 84(5):1064-1067. PubMed ID: 29384591
[TBL] [Abstract][Full Text] [Related]
50. PREVALENCE OF FATIGUE AND IMPACT ON QUALITY OF LIFE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: the VITAL study.
Rodríguez Antolín A; Martínez-Piñeiro L; Jiménez Romero ME; García Ramos JB; López Bellido D; Muñoz Del Toro J; García García-Porrero A; Gómez Veiga F
BMC Urol; 2019 Oct; 19(1):92. PubMed ID: 31619215
[TBL] [Abstract][Full Text] [Related]
51. Epidemiology of metastatic castration-resistant prostate cancer: A first estimate of incidence and prevalence using the French nationwide healthcare database.
Thurin NH; Rouyer M; Gross-Goupil M; Rebillard X; Soulié M; Haaser T; Roumiguié M; Le Moulec S; Capone C; Pierrès M; Lamarque S; Jové J; Bignon E; Droz-Perroteau C; Moore N; Blin P
Cancer Epidemiol; 2020 Dec; 69():101833. PubMed ID: 33068878
[TBL] [Abstract][Full Text] [Related]
52. Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer.
Cunningham JJ; Brown JS; Gatenby RA; Staňková K
J Theor Biol; 2018 Dec; 459():67-78. PubMed ID: 30243754
[TBL] [Abstract][Full Text] [Related]
53. Drug-drug interactions associated with length of stay and cost of hospitalization.
Moura CS; Acurcio FA; Belo NO
J Pharm Pharm Sci; 2009; 12(3):266-72. PubMed ID: 20067703
[TBL] [Abstract][Full Text] [Related]
54. Urological cancer: abiraterone treatment improves overall survival in patients with mCRPC.
Sidaway P
Nat Rev Clin Oncol; 2015 Mar; 12(3):128. PubMed ID: 25645601
[No Abstract] [Full Text] [Related]
55. Risk factors for unplanned discontinuation of scheduled treatment in elderly patients with castration-resistant prostate cancer: results of the IBuTu study.
Honecker F; Wedding U; Kallischnigg G; Schroeder A; Klier J; Frangenheim T; Weißbach L
J Cancer Res Clin Oncol; 2018 Mar; 144(3):571-577. PubMed ID: 29299751
[TBL] [Abstract][Full Text] [Related]
56. Hypersensitivity reaction to Abiraterone, successful desensitization protocol in prostate cancer patient.
González Díaz SN; Vidal Gutiérrez O; Rodríguez Román JC; López Henríquez RA; Macouzet Sánchez C; de Lira Quezada CE; Acuña Ortega N
J Oncol Pharm Pract; 2024 Jun; 30(4):777-779. PubMed ID: 38486509
[TBL] [Abstract][Full Text] [Related]
57. Statin-Induced Rhabdomyolysis Due to Pharmacokinetic Changes From Biliary Obstruction in a Patient With Metastatic Prostate Cancer.
Desikan SP; Sobash P; Fisher A; Desikan R
J Investig Med High Impact Case Rep; 2020; 8():2324709620947275. PubMed ID: 32755252
[TBL] [Abstract][Full Text] [Related]
58. Prevalence and differences in the co-administration of drugs known to interact: an analysis of three distinct and large populations.
Sánchez-Valle J; Correia RB; Camacho-Artacho M; Lepore R; Mattos MM; Rocha LM; Valencia A
BMC Med; 2024 Apr; 22(1):166. PubMed ID: 38637816
[TBL] [Abstract][Full Text] [Related]
59. Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States.
Wallace KL; Landsteiner A; Bunner SH; Engel-Nitz NM; Luckenbaugh AN
Cancer Causes Control; 2021 Dec; 32(12):1365-1374. PubMed ID: 34386852
[TBL] [Abstract][Full Text] [Related]
60. Prevalence of cytochrome P450-mediated potential drug-drug interactions in residents of intermediate care facilities for older adults in Japan.
Hamada S; Ohno Y; Kojima T; Ishii S; Okochi J; Akishita M
Geriatr Gerontol Int; 2019 Jun; 19(6):513-517. PubMed ID: 30912281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
